| Literature DB >> 35457729 |
Julian S O Campbell1, Saskia van Henten2, Zikan Koroma3, Ibrahim Franklyn Kamara4, Gladys N Kamara5, Hemant Deepak Shewade6, Anthony D Harries7,8.
Abstract
In sub-Saharan Africa, there is limited information about the use of microbiology laboratory services in patients with suspected urinary tract infections (UTIs). This cross-sectional study assessed the requests for urine culture in patients with suspected UTI in two tertiary (maternal and paediatric) hospitals-Freetown and Sierra Leone, during May 2017-May 2021-and determined antimicrobial resistance (AMR) patterns among bacterial isolates. One laboratory served the two hospitals, with its electronic database used to extract information. Overall, there were 980 patients, of whom 168 (17%) had cultures requested and performed. Of these, 75 (45%) were culture positive. During 2017-2019, there were 930 patients, of whom 156 (17%) had cultures performed. During 2020-2021, when services were disrupted by the COVID-19 pandemic, there were 50 patients, of whom 12 (24%) had cultures performed. The four commonest isolates were Escherichia coli (36), Klebsiella pneumoniae (10), Staphylococcus aureus (9), and Pseudomonas spp. (6). There were high levels of AMR, especially for trimethoprim-sulfamethoxazole (47%), nalidixic acid (44%), nitrofurantoin (32%) and cefotaxime (36%). Overall, 41 (55%) bacterial isolates showed multidrug resistance, especially E. coli (58%), Pseudomonas spp. (50%), and S. aureus (44%). These findings support the need for better utilization of clinical microbiology services to guide antibiotic stewardship and monitoring of trends in resistance patterns.Entities:
Keywords: SORT IT; Sierra Leone; West Africa; antibiotic sensitivity testing; children; culture requests; operational research; pregnant women; secondary data; uropathogens
Mesh:
Substances:
Year: 2022 PMID: 35457729 PMCID: PMC9024669 DOI: 10.3390/ijerph19084865
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Numbers of patients with suspected urinary tract infections, culture requests, and those processed through to positive cultures in the two hospitals in Freetown, Sierra Leone, between May 2017 and May 2021. UTI—urinary tract infection; MDR—multidrug resistant; * all culture requests underwent urine culture; a denominator is suspected UTI; b denominator is culture requested; c denominator is culture positive.
Figure 2Numbers of patients with suspected urinary tract infections, culture requests, and those processed through to positive cultures in the two hospitals in Freetown, Sierra Leone, between May 2017 and May 2021. UTI—urinary tract infection; * all culture requests underwent urine culture; a denominator is suspected UTI; b denominator is culture requested.
Bacterial isolates and their antimicrobial resistance patterns in culture-positive urine samples in two hospitals in Freetown, Sierra Leone, between May 2017 and May 2021 [N = 75].
| Isolates and Their Resistance Patterns |
|
|
| Coliforms |
| Other * | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | |
| Total isolates | 36 | 10 | 9 | 6 | 4 | 3 | 7 | 75 | ||||||||
| Resistant to | ||||||||||||||||
| Cephalothin A | 5 | (14) | - | - | - | - | - | - | 1 | (25) | - | - | 3 | (43) | 9 | (12) |
| Gentamicin A | 3 | (8) | 1 | (10) | 2 | (22) | - | - | - | - | 2 | (67) | 3 | (43) | 11 | (15) |
| Ciprofloxacin Wa | 6 | (17) | 1 | (10) | - | - | - | - | - | - | 1 | (33) | 3 | (43) | 11 | (15) |
| Colistin Sulphate Re | 2 | (6) | - | - | 2 | (22) | - | - | 1 | (25) | - | - | 2 | (29) | 7 | (9) |
| Nalidixic acid | 15 | (42) | 2 | (20) | 4 | (44) | 1 | (17) | 1 | (25) | 3 | (100) | 7 | (100) | 33 | (44) |
| Nitrofurantoin A | 10 | (28) | 4 | (40) | - | - | 4 | (67) | 2 | (50) | 1 | (33) | 3 | (43) | 24 | (32) |
| TMP-SMX A | 17 | (47) | 4 | (40) | - | - | 3 | (50) | 4 | (100) | 2 | (67) | 5 | (71) | 35 | (47) |
| Cefotaxime Wa | 14 | (39) | 2 | (20) | 6 | (67) | 2 | (33) | - | - | - | - | 3 | (43) | 27 | (36) |
| Oxacillin A | - | - | - | - | - | - | - | - | - | - | - | - | 1 | (14) | 1 | (1) |
| Erythromycin Wa | - | - | - | - | - | - | - | - | - | - | - | - | 1 | (14) | 1 | (1) |
| Imipenem Wa | 3 | (8) | - | - | - | - | 2 | (33) | - | - | - | - | 1 | (14) | 6 | (8) |
| Multi-drug resistance | 21 | (58) | 2 | (20) | 4 | (44) | 3 | (50) | 1 | (25) | 3 | (100) | 7 | (100) | 41 | (55) |
Column percentages: E. coli—Escherichia coli; S. aureus—Staphylococcus aureus; TMP-SMX—trimethoprim-sulfamethoxazole. A—Aware group, Wa—watch group, Re—reserve group of antibiotics [13]. -: the antibiotic disks were not used on the bacterial isolate. * Other: Staphylococcus saprophyticus (2), Micrococcus spp. (2), Enterococcus faecalis (2), Acinetobacter spp. (1).